Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 6, 2007

MitoPharm Licenses New Extraction Method

  • MitoPharm signed an exclusive, worldwide licensing agreement with the Hong Kong University of Science and Technology for the use and commercialization of its patent-pending process for the extraction of (-) Schisandrin B and Schisandrin B.

    MitoPharm reports that it thus gains the first commercial-scale process for the extraction of Schisandrin B that delivers a high degree of purity and well-defined bacterial levels. The process incorporates hybrid chromatography, which is widely used in the fine chemical and pharmaceutical industries for the recovery of high-purity products.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »